Niederer Kraft Frey advises DKSH on NewBridge acquisition

Niederer Kraft Frey (NKF) has advised DKSH on its agreement to acquire 100 per cent of NewBridge Pharmaceuticals for an enterprise value of USD 390 million. The transaction is subject to customary closing conditions.

Deal details

The agreement gives DKSH full ownership of NewBridge Pharmaceuticals, a healthcare commercialization platform headquartered in Dubai. The acquisition is intended to extend the footprint of DKSH’s Healthcare business beyond Asia Pacific. It also supports the unit’s strategic roadmap of becoming a multi-regional, end-to-end outsourcing platform.

About the parties

DKSH is a market expansion services provider listed on the SIX Swiss Exchange. It operates in Asia Pacific, Europe and North America through four business units: healthcare, consumer goods, performance materials and technology.

Advisers

The NKF team was led by corporate/M&A partners Deirdre Ni Annrachain and Patrik Peyer, together with financing partner Philip Spoerlé. They worked with associates Lorenzo Henseler and Leonard Reiter, both from the financing practice.

Pictured from left to right: Deirdre Ni Annrachain, Patrik Peyer, and Philip Spoerlé